HIFRENZO Trademark

Trademark Overview


On Friday, March 17, 2023, a trademark application was filed for HIFRENZO with the United States Patent and Trademark Office. The USPTO has given the HIFRENZO trademark a serial number of 97844505. The federal status of this trademark filing is FIRST EXTENSION - GRANTED as of Tuesday, August 27, 2024. This trademark is owned by AstraZeneca AB. The HIFRENZO trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations and substances for use in oncology; Pharmaceutical preparations and substances for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, neurological, gastrointestinal and immune systems; Pharmaceutical preparations and substances for the treatment of infection, inflammation, hematological, autoimmune related diseases and disorders; Pharmaceutical preparations and substances, namely, antibodies; vaccines
hifrenzo

General Information


Serial Number97844505
Word MarkHIFRENZO
Filing DateFriday, March 17, 2023
Status730 - FIRST EXTENSION - GRANTED
Status DateTuesday, August 27, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 23, 2024

Trademark Statements


Goods and ServicesPharmaceutical preparations and substances for use in oncology; Pharmaceutical preparations and substances for the treatment of diseases and disorders of the cardiovascular, renal, metabolic, respiratory, nervous, neurological, gastrointestinal and immune systems; Pharmaceutical preparations and substances for the treatment of infection, inflammation, hematological, autoimmune related diseases and disorders; Pharmaceutical preparations and substances, namely, antibodies; vaccines

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateThursday, March 23, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameFIBROGEN, INC.
Party Type21 - New Owner After Publication
Legal Entity Type03 - Corporation
AddressSAN FRANCISCO, CA 94158

Party NameAstraZeneca AB
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressSödertälje SE-15185
SE

Party NameAstraZeneca AB
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressSödertälje SE-15185
SE

Trademark Events


Event DateEvent Description
Tuesday, March 21, 2023NEW APPLICATION ENTERED
Thursday, March 23, 2023NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Wednesday, December 13, 2023ASSIGNED TO EXAMINER
Wednesday, December 20, 2023APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, January 3, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 23, 2024PUBLISHED FOR OPPOSITION
Tuesday, January 23, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 19, 2024NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, April 3, 2024AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP
Monday, August 26, 2024TEAS WITHDRAWAL OF ATTORNEY RECEIVED-FIRM RETAINS
Monday, August 26, 2024ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Monday, August 26, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Monday, August 26, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Monday, August 26, 2024TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Monday, August 26, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Tuesday, August 27, 2024SOU TEAS EXTENSION RECEIVED
Tuesday, August 27, 2024NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Tuesday, August 27, 2024SOU EXTENSION 1 FILED
Tuesday, August 27, 2024SOU EXTENSION 1 GRANTED